The first histopathological evidence of trimetazidine for the prevention of contrast-induced nephropathy.
OBJECTIVE
We aimed to investigate the prophylactic effects of trimetazidine (TMZ) against contrast-induced nephropathy (CIN) in rat kidneys.


RESULTS
28 Wistar rats were divided into 4 groups of 7 rats each (control (C), contrast media (CM) TMZ, trimetazidin+contrast media groups (TMZ + CM). The administration of TMZ solution was done on d2, d3 and d4. Fifth day, contrast media was administered at a single dose. On d6 scarification was performed. The oxidant/antioxidant parameters were measured and histopathological scores were performed in kidney tissues. Most of the histopathological scores were significantly higher in the CM group as compared to other groups. Moreover, the scores of the TMZ + CM and C groups were not statistically different. CM group, had significantly higher levels of MDA compared to the C and CM + TMZ groups (562.82 ± 38.15 vs. 419.15 ± 49.01 and 507.34 ± 14.16 01 nmol/mg protein respectively) (p<0.001). CM group had significantly lower levels of SOD as compared to C, CM + TMZ and TMZ groups (p<0.05).


CONCLUSIONS
To the best of our knowledge, this study for the first time, histopathologically demonstrated the effectiveness of TMZ for the prevention of CIN.
Department of Cardiology, Medical Faculty, Adnan Menderes University , Aydin , Turkey .
Çağdaş
Ç
Akgüllü
Tevger
T
Saruhan
Ufuk
U
Eryilmaz
Murat
M
Boyacıoğlu
Osman Alper
OA
Onbaşılı
Ibrahim
I
Meteoğlu
Cavit
C
Kum
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001835:Body Weight; D002374:Catalase / Q000378:metabolism; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D005978:Glutathione / Q000378:metabolism; D007668:Kidney / Q000378:metabolism / Q000473:pathology*; D007674:Kidney Diseases / Q000139:chemically induced / Q000473:pathology* / Q000517:prevention & control*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009929:Organ Size; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism; D014292:Trimetazidine / Q000627:therapeutic use*
D000975:Antioxidants; D003287:Contrast Media; D008315:Malondialdehyde; D003404:Creatinine; D002374:Catalase; D013482:Superoxide Dismutase; D005978:Glutathione; D014292:Trimetazidine